Castration Resistant Prostatic Neoplasms Completed Phase 1 Trials for Cetrelimab (DB15421)

Also known as: Prostate Neoplasms, Castration-resistant / Castration-Resistant Prostatic Neoplasms / Prostatic Neoplasms, Castration-Resistant

DBCOND0129140 (Castration Resistant Prostatic Neoplasms)Completed1 IdentifierTitlePurposeDrugs
NCT03551782A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerTreatment